RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as docetaxel, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. It is not yet known whether giving
everolimus together with docetaxel is more effective than giving docetaxel alone in treating
patients with head and neck cancer.
PURPOSE: This phase I/II trial is studying the side effects and best dose of everolimus given
together with docetaxel in treating patients with recurrent, locally advanced, or metastatic
head and neck cancer.